Clinical trial · Interventional
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
NCT02309632CI-TRIAL-00039769withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of funding
Summary
Brief summary (as posted)
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ataxia Telangiectasia | — | UNRESOLVED | — |
| BRCA1 Gene Mutation | — | UNRESOLVED | — |
| BRCA2 Gene Mutation | — | UNRESOLVED | — |
| Colorectal Neoplasms, Hereditary Nonpolyposis | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.85 |
| Familial Atypical Mole-Malignant Melanoma Syndrome | — | UNRESOLVED | — |
| Hereditary Pancreatitis | — | UNRESOLVED | — |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Peutz-Jegher's Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pancreatic Cancer Screening Pathway 1 | Other | — | UNRESOLVED |
| Pancreatic Cancer Screening Pathway 2 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Pathway 1
- description
- Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
- interventionNames
- Other: Pancreatic Cancer Screening Pathway 1
- type
- ACTIVE_COMPARATOR
- label
- Pathway2
- description
- Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
- interventionNames
- Other: Pancreatic Cancer Screening Pathway 2
Primary outcomes (1)
- measure
- Detection rate of PC and precancerous lesion
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Have a family history of PC as listed below or who have one of the following syndromes: Peutz-Jeghers syndrome - STK11; BRCA 1 and 2; PALB2; ATM; FAMMM / P16; HNPCC (Lynch) / MMR genes; Hereditary pancreatitis - PRSS1 * Individuals with three or more affected blood relatives (1st, 2nd or 3rd degree) * Individuals with two or more affected blood relatives with PC, with at least one affected FDR, should be considered for screening. * Patients with a history of Peutz-Jeghers syndrome should be screened, regardless of family history of PC. * Patients with a known p16 (FAMMM syndrome) with one affected 1st or 2nd degree relative will be considered for screening. * Patients with a known BRCA1 or BRCA2 mutation with one affected 1st or 2nd degree relative should be considered for screening. * Patients with a known PALB2 mutation with one affected family member should be considered for screening. * Patients with a known Mismatch-repair gene-mutation carriers (Lynch syndrome) with one affected family member should be considered for screening. Exclusion Criteria: * Not candidates for surgery
References
Publications (0)
Data not yet available
No reference posted for this study.